ClinicalTrials.gov
Cure8 trial brief
Why This Matters
A new Phase 3 trial is testing duvakitug as a potential induction therapy for moderate-to-severe ulcerative colitis. Trial results could add another treatment option if the drug proves safe and effective.
Who Should Pay Attention
Adults with moderately to severely active ulcerative colitis, clinicians and researchers following investigational therapies, and patients interested in clinical trial participation.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 3
Enrollment980 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a Phase 3, randomized, double-blind, placebo-controlled induction trial (NCT07184996) testing duvakitug, a subcutaneously injected investigational therapy, for moderately to severely active ulcerative colitis. The induction period is up to 12 weeks with a primary endpoint of clinical remission at Week 12 using a modified Mayo Score (mMS).
The study plans to enroll about 980 participants across multiple international sites and includes an extended induction sub-study for non-responders as well as a feeder open-label sub-study. The record lists basic eligibility (age 16–80 where permitted, prior therapies restrictions) and safety follow-up.
This entry describes the trial design, interventions (duvakitug vs placebo SC injections), scheduled visits, and primary outcome; it does not report results or safety outcomes.
If you are considering participation, the clinicaltrials.gov record is the authoritative source for full inclusion/exclusion criteria, site locations, and contact information; discuss eligibility and risks with the trial site and your treating clinician.
Keep In Mind
This is a trial registration record (Phase 3, recruiting) and reports the study design and planned outcomes; it does not provide efficacy or safety results. Participants previously exposed to anti‑TL1A investigational therapy were excluded per the record. Check the trial entry or contact study coordinators for the latest status and detailed criteria.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorSanofi
Trial IDNCT07184996
Study typeInterventional
Trial phasePhase 3
Enrollment980 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 20, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be...
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...